Retrospective study on chemotherapy – induced anaemia: incidence, treatment patterns and outcomes in a tertiary care hospital in South India

D. Sowmiya; B. Suthish; K. Bhuvaneswari

doi:10.18203/2319-2003.ijbcp20260337

Authors

D. Sowmiya Department of Pharmacology, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India
B. Suthish Department of Pharmacology, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India
K. Bhuvaneswari Department of Pharmacology, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20260337

Keywords:

Anaemia, Chemotherapy, Haemoglobin, Antineoplastic agents, Blood transfusion

Abstract

Background: Chemotherapy-induced anaemia (CIA) is a common complication in cancer patients and can negatively affect treatment continuity and quality of life. The severity of anaemia may vary depending on the chemotherapeutic drug class. This study aimed to evaluate the incidence, severity, management, and outcomes of CIA in a tertiary care hospital.

Methods: A retrospective observational study was conducted among 100 cancer patients who received chemotherapy between January 2024 and December 2024. Demographic data, cancer diagnosis, chemotherapy regimens, haemoglobin levels before and after chemotherapy, anaemia grading, management strategies, and outcomes were collected. Haemoglobin changes were analysed using paired t-test, and differences between drug classes were assessed using one-way ANOVA.

Results: Mean haemoglobin levels decreased significantly from 13.40±0.90 g/dl before chemotherapy to 9.49±1.47 g/dl after chemotherapy (mean reduction 3.91±1.65 g/dl; p<0.001). Grade 1 anaemia was observed in 52% of patients, grade 2 in 27%, grade 3 in 15%, and grade 4 in 6%. Haemoglobin reduction differed significantly among drug classes (F=5.917, p=0.0001), with greater reductions seen with alkylating agents, taxanes, and PD-1 receptor inhibitors. Iron therapy (40%) and blood transfusions (19%) were the most common management strategies. Clinical improvement was observed in 97% of patients.

Conclusions: Chemotherapy causes a significant reduction in haemoglobin levels, with variability across drug classes. Regular monitoring and appropriate management of anaemia are essential during chemotherapy.

Metrics

Metrics Loading ...

References

Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293-306. DOI: https://doi.org/10.1016/j.ejca.2004.06.019

Saint A, Viotti J, Borchiellini D, Hoch B, Raimondi V, Hebert C, et al. Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study. Support Care Cancer. 2020;28(4):1639-47. DOI: https://doi.org/10.1007/s00520-019-04938-3

Macciò A, Madeddu C, Gramignano G, Mulas C, Tanca L, Cherchi MC, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large prospective observational study. Haematologica. 2015;100(1):124-32. DOI: https://doi.org/10.3324/haematol.2014.112813

Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. Blood. 2020;136(7):801-13. DOI: https://doi.org/10.1182/blood.2019004017

Abdel-Razeq H, Hashem H. Recent update in the pathogenesis and treatment of chemotherapy- and cancer-induced anemia. Crit Rev Oncol Hematol. 2020;145:102837. DOI: https://doi.org/10.1016/j.critrevonc.2019.102837

Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40-50. DOI: https://doi.org/10.1182/blood-2018-06-856500

Camaschella C, Girelli D. The changing landscape of iron deficiency. Mol Aspects Med. 2020;75:100861. DOI: https://doi.org/10.1016/j.mam.2020.100861

Busti F, Marchi G, Ugolini S, Castagna A, Girelli D. Anemia and iron deficiency in cancer patients: role of iron replacement therapy. Pharmaceuticals (Basel). 2018;11(4):94. DOI: https://doi.org/10.3390/ph11040094

Xu H, Xu L, Page JH, Cannavale K, Sattayapiwat O, Rodriguez R, et al. Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010-2013. Clin Epidemiol. 2016;8:61-71. DOI: https://doi.org/10.2147/CLEP.S89480

Cannavale K, Xu H, Xu L, Sattayapiwat O, Rodriguez R, Bohac C, et al. Epidemiology of chemotherapy-induced anemia in patients with non-Hodgkin lymphoma. Perm J. 2019;23:18-252. DOI: https://doi.org/10.7812/TPP/18-252

Family L, Xu L, Xu H, Cannavale K, Sattayapiwat O, Page JH, et al. The effect of chemotherapy-induced anemia on dose reduction and dose delay. Support Care Cancer. 2016;24(10):4263-71. DOI: https://doi.org/10.1007/s00520-016-3258-3

Badheeb AM, Ahmed F, Badheeb MA, Obied HY, Seada IA, Al Jumman A, et al. Anemia profiles in cancer patients: prevalence, contributing factors, and insights from a retrospective study at a single cancer center in Saudi Arabia. Cureus. 2023;15(7):e42400. DOI: https://doi.org/10.7759/cureus.42400

Wondm SA, Dagnew SB, Gubae K, Tesfaye TC, Tamene FB. Determinants of anemia among patients receiving cancer chemotherapy in Northwest Ethiopia. Front Med (Lausanne). 2024;11:1415877. DOI: https://doi.org/10.3389/fmed.2024.1415877

Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019;6(1):e48-57. DOI: https://doi.org/10.1016/S2352-3026(18)30175-3

Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer. 2001;91(12):2214-21. DOI: https://doi.org/10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P

Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2009;(3):CD003407.